United Therapeutics | UTHR - Sales Revenues

Stock Price
568.58
Daily Change
-7.21 -1.25%
Monthly
-2.06%
Yearly
86.21%
Q2 Forecast
557.15

United Therapeutics reported $781.5M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Amarin USD 49.22M 451K Dec/2025
Ardelyx USD 94.47M 30.74M Mar/2026
Baxter International USD 2.7B 270M Mar/2026
Bayer EUR 13.41B 1.97B Mar/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Biogen USD 2.25B 30M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Gilead Sciences USD 7B 930M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Halozyme Therapeutics USD 377M 74.76M Mar/2026
Insmed USD 305.96M 42.16M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
J&J USD 24.1B 500M Mar/2026
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
Moderna USD 389M 289M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
PTC Therapeutics USD 273M 108.3M Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Teva Pharmaceutical Industries USD 11.77B 2.86B Mar/2026
United Therapeutics USD 781.5M 8.7M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026